FDA issues guidance to help generic drug applicants in ensuring the protection of participants resuming or initiating bioequivalence (BE) studies conducted to support the approval of an ANDA that has been disrupted during #COVID19: https://t.co/Ay06sXCoGqhttps://t.co/1kg2o6ga67
FDA’s Pandemic Recovery and Preparedness Plan initiative strengthens ongoing #COVID19 pandemic response and our resiliency for future public health emergencies. Find out more in #FDAVoices. https://t.co/qeLUPBVjv1
If a prescription drug sounds too good to be true, it might just be. Learn about recognizing and reporting potentially false or misleading prescription drug promotion with FDA’s Bad Ad Program and its free 1-hr CE course: https://t.co/JHYqwQT67y#FDABadAdhttps://t.co/BNSRKW0NYD
Join us on Feb 2-3 for a virtual public meeting to provide input on the scientific and ethical issues that surround the inclusion of pregnant women in clinical trials for drug development.
National Pharmacists Day is January 12 so make sure to thank yours for helping keep you healthy. They are on the front lines educating you on how to safely take medicines, like tranquilizers featured in this PSA. #FDAhistory#TuesdayThoughtshttps://t.co/W42YpeffsQ
Today, we issued the Focus Areas of Regulatory Science report, which outlines areas of research that are organized by my strategic initiatives that I shared at the beginning of last year. https://t.co/2PxfdFqsRJhttps://t.co/IUHVjCYYG0